Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
Background
Lorigerlimab (previously known as MGD019) is an investigational, bispecific DART® molecule that was designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes compared to a PD-1/CTLA-4 monoclonal antibody (mAb) combination therapy, while maintaining maximal PD-1 blockade on all PD-1-expressing cells.
Clinical Development
Based upon the establishment of a recommended Phase 2 dose from a dose escalation study, lorigerlimab is being evaluated in a dose expansion study in microsatellite-stable colorectal cancer, non-small cell lung cancer, metastatic castration-resistant prostate cancer and melanoma.
MacroGenics is also evaluating the activity of MGC018 (an investigational B7-H3-directed antibody-drug conjugate) plus lorigerlimab in a Phase 1 study of patients with advanced solid tumors.
Our Rights
MacroGenics retains global rights to lorigerlimab.
Clinical Trials
- Lorigerlimab (MGD019) Phase 1 dose escalation study (NCT03761017)
- MGC018 in Combination With Lorigerlimab Phase 1 Study in Advanced Solid Tumors (NCT05293496)
Presentations & Publications
Relevant Publications and Presentations can be found at https://www.macrogenics.com/publications/.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.